Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Лечение пациентов с артериальной гипертензией: как добиться результата и повысить приверженность
Лечение пациентов с артериальной гипертензией: как добиться результата и повысить приверженность
Стрюк Р.И. Лечение пациентов с артериальной гипертензией: как добиться результата и повысить приверженность. Consilium Medicum. 2015; 17 (12): 8–12. DOI:10.26442/2075-1753_2015.12.8-12
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Артериальная гипертензия (АГ) в индустриально развитых странах, в том числе в России, занимает первое место по вкладу в смертность от сердечно-сосудистых заболеваний. Основной целью ее лечения является максимальное снижение долгосрочного сердечно-сосудистого риска, что достигается, наряду с коррекцией модифицируемых факторов риска, проведением адекватной антигипертензивной терапии с учетом органопротекции и метаболической нейтральности препаратов. Целевого уровня артериального давления можно достичь более ранним назначением комбинированной антигипертензивной терапии, в том числе в виде фиксированных комбинаций (ФК). Одной из таких ФК является Конкор АМ, содержащий бисопролол и амлодипин, который показал высокую клиническую эффективность, хорошую приверженность лечению и минимальное число побочных эффектов не только у пациентов с АГ, но и при сочетании АГ с другими коморбидными состояниями.
Ключевые слова: артериальная гипертензия, фиксированная комбинация бисопролола и амлодипина.
Ключевые слова: артериальная гипертензия, фиксированная комбинация бисопролола и амлодипина.
________________________________________________
Arterial hypertension in industrialized countries, including Russia, has the highest contribution to the mortality from cardiovascular disease. The main goal of treatment is to maximize its long-term reduction in cardiovascular risk, which is achieved, along with the correction of modifiable risk factors, conduct adequate antihypertensive therapy based on organo and metabolic neutrality drugs. Target blood pressure level can be achieved earlier appointment combined antihypertensive therapy, including in the form of fixed combinations (FC). One of these is the FC Concor AM containing bisoprolol and amlodipine, which has shown high clinical efficiency, good adherence and the minimum number of side effects, not only in patients with hypertension, but also with a combination of hypertension with other comorbid conditions.
Key words: arterial hypertension, the fixed combination of amlodipine and bisoprolol.
Key words: arterial hypertension, the fixed combination of amlodipine and bisoprolol.
Полный текст
Список литературы
1. Kannel WB. Blood pressure as a cardiovascular risk factor. Prevention and treatment. JAMA 1996; 275: 1576.
2. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 10: 4–12. / Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 10: 4–12. [in Russian]
3. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–219.
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106 (25): 3143–421.
5. Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.
6. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399–407.
7. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122 (3): 290–300.
8. Леонова М.В., Штейнберг Л.Л., Белоусов Ю.Б. и др. Фармакоэпидемиология артериальной гипертонии в России: анализ приверженности врачей (по результатам исследования ПИФАГОР IV). Системные гипертензии. 2015; 1: 19–25. / Leonova M.V., Shteinberg L.L., Belousov Iu.B. i dr. Farmakoepidemiologiia arterial'noi gipertonii v Rossii: analiz priverzhennosti vrachei (po rezul'tatam issledovaniia PIFAGOR IV). Systemic Hypertension. 2015; 1: 19–25. [in Russian]
9. Lee S-A, Choi H-M, Park H-J et al. Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy. Korean J Intern Med 2014; 29: 315–24.
10. Wang JG, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview. Hypertension 2007; 50: 181–8.
11. Mancia G, Grassi. Combination treatment of hypertension. High Blood Pressure1994; 5: 5–7.
12. Elliott W, Meyer P. Incident diabetes in clinical trial of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7.
13. Fleckenstein A, Tritthard H, Fleckenstein B et al. Pflugers Arch Physiol 1969; 307: 25.
14. Angeli F, Verdecchia P, Reboldi GP et al. Calcium channel blockade to prevent stroke in hypertension: meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens 2004; 17 (9): 817–22.
15. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503–10.
16. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–26.
17. Преображенский Д.В., Вышинская И.Д., Некрасова Н.И. Бисопролол – высокоселективный бета-адреноблокатор: клиническая фармакология и опыт при лечении сердечно-сосудистых заболеваний. Consilium Medicum. 2010; 10 (11): 138–43. / Preobrazhenskii D.V., Vyshinskaia I.D., Nekrasova N.I. Bisoprolol – vysokoselektivnyi beta-adrenoblokator: klinicheskaia farmakologiia i opyt pri lechenii serdechno-sosudistykh zabolevanii. Consilium Medicum. 2010; 10 (11): 138–43. [in Russian]
18. Jabbour A, Macdonald PS, Keogh AM et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized cross-over trial. J Am Coll Cardiol 2010; 55 (17): 1780–7.
19. Kjekshus JK. Comments on beta-blockers: heart rate reduction, a mechanism of action. Eur Heart J 1985; 6: 29.
20. Bоhn M, Cotton D, Foster L et al. Impact of resting heart rate on mortality, disability, cognitive decline in patients after ischaemic stroke. Eur Heart J 2012; 33: 2804–12.
21. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and ounger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121–3.
22. Czarnecka D, Koch EMW, Gottwald-Hostalek U. Benefits of afixed-dose combination of bisoprolol and amlodipine in the treatment of hypertension in daily practice: results of more than 4000 patients. Curr Med Res Opin 2015; 1–7.
23. Hostalek Ulrike, Czarnecka Danuta, Koch Ernst MW. Treatment of Hypertensive Patients with a Fixed-Dose Combination of Bisoprolol and Amlodipine: Results of a Cohort study with More Than 10,000 Patients. The Author (s) 2015. http://creativecommons.org/licenses/ by-nc/4.0/
24. Недогода С.В., Саласюк А.С., Цома В.В., Чумачек Е.В. Влияние фиксированной комбинации амлодипина и бисопролола на сосудистую эластичность у пациентов с артериальной гипертензией. Consilium Medicum. 2015; 17 (10): 8–11. / Nedogoda S.V., Salasiuk A.S., Tsoma V.V., Chumachek E.V. Vliianie fiksirovannoi kombinatsii amlodipina i bisoprolola na sosudistuiu elastichnost' u patsientov s arterial'noi gipertenziei. Consilium Medicum. 2015; 17 (10): 8–11. [in Russian]
25. Чесникова А.И., Сафроненко В.А., Коломацкая О.Е. Оценка эффективности фиксированной комбинации бисопролола и амлодипина в амбулаторном лечении больных с артериальной гипертонией и ишемической болезнью сердца. Кардиология. 2014; 9: 7–23. / Chesnikova A.I., Safronenko V.A., Kolomatskaia O.E. Otsenka effektivnosti fiksirovannoi kombinatsii bisoprolola i amlodipina v ambulatornom lechenii bol'nykh s arterial'noi gipertoniei i ishemicheskoi bolezn'iu serdtsa. Kardiologiia. 2014; 9: 7–23. [in Russian]
2. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 10: 4–12. / Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 10: 4–12. [in Russian]
3. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–219.
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106 (25): 3143–421.
5. Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.
6. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399–407.
7. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122 (3): 290–300.
8. Леонова М.В., Штейнберг Л.Л., Белоусов Ю.Б. и др. Фармакоэпидемиология артериальной гипертонии в России: анализ приверженности врачей (по результатам исследования ПИФАГОР IV). Системные гипертензии. 2015; 1: 19–25. / Leonova M.V., Shteinberg L.L., Belousov Iu.B. i dr. Farmakoepidemiologiia arterial'noi gipertonii v Rossii: analiz priverzhennosti vrachei (po rezul'tatam issledovaniia PIFAGOR IV). Systemic Hypertension. 2015; 1: 19–25. [in Russian]
9. Lee S-A, Choi H-M, Park H-J et al. Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy. Korean J Intern Med 2014; 29: 315–24.
10. Wang JG, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview. Hypertension 2007; 50: 181–8.
11. Mancia G, Grassi. Combination treatment of hypertension. High Blood Pressure1994; 5: 5–7.
12. Elliott W, Meyer P. Incident diabetes in clinical trial of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7.
13. Fleckenstein A, Tritthard H, Fleckenstein B et al. Pflugers Arch Physiol 1969; 307: 25.
14. Angeli F, Verdecchia P, Reboldi GP et al. Calcium channel blockade to prevent stroke in hypertension: meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens 2004; 17 (9): 817–22.
15. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503–10.
16. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–26.
17. Преображенский Д.В., Вышинская И.Д., Некрасова Н.И. Бисопролол – высокоселективный бета-адреноблокатор: клиническая фармакология и опыт при лечении сердечно-сосудистых заболеваний. Consilium Medicum. 2010; 10 (11): 138–43. / Preobrazhenskii D.V., Vyshinskaia I.D., Nekrasova N.I. Bisoprolol – vysokoselektivnyi beta-adrenoblokator: klinicheskaia farmakologiia i opyt pri lechenii serdechno-sosudistykh zabolevanii. Consilium Medicum. 2010; 10 (11): 138–43. [in Russian]
18. Jabbour A, Macdonald PS, Keogh AM et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized cross-over trial. J Am Coll Cardiol 2010; 55 (17): 1780–7.
19. Kjekshus JK. Comments on beta-blockers: heart rate reduction, a mechanism of action. Eur Heart J 1985; 6: 29.
20. Bоhn M, Cotton D, Foster L et al. Impact of resting heart rate on mortality, disability, cognitive decline in patients after ischaemic stroke. Eur Heart J 2012; 33: 2804–12.
21. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and ounger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121–3.
22. Czarnecka D, Koch EMW, Gottwald-Hostalek U. Benefits of afixed-dose combination of bisoprolol and amlodipine in the treatment of hypertension in daily practice: results of more than 4000 patients. Curr Med Res Opin 2015; 1–7.
23. Hostalek Ulrike, Czarnecka Danuta, Koch Ernst MW. Treatment of Hypertensive Patients with a Fixed-Dose Combination of Bisoprolol and Amlodipine: Results of a Cohort study with More Than 10,000 Patients. The Author (s) 2015. http://creativecommons.org/licenses/ by-nc/4.0/
24. Недогода С.В., Саласюк А.С., Цома В.В., Чумачек Е.В. Влияние фиксированной комбинации амлодипина и бисопролола на сосудистую эластичность у пациентов с артериальной гипертензией. Consilium Medicum. 2015; 17 (10): 8–11. / Nedogoda S.V., Salasiuk A.S., Tsoma V.V., Chumachek E.V. Vliianie fiksirovannoi kombinatsii amlodipina i bisoprolola na sosudistuiu elastichnost' u patsientov s arterial'noi gipertenziei. Consilium Medicum. 2015; 17 (10): 8–11. [in Russian]
25. Чесникова А.И., Сафроненко В.А., Коломацкая О.Е. Оценка эффективности фиксированной комбинации бисопролола и амлодипина в амбулаторном лечении больных с артериальной гипертонией и ишемической болезнью сердца. Кардиология. 2014; 9: 7–23. / Chesnikova A.I., Safronenko V.A., Kolomatskaia O.E. Otsenka effektivnosti fiksirovannoi kombinatsii bisoprolola i amlodipina v ambulatornom lechenii bol'nykh s arterial'noi gipertoniei i ishemicheskoi bolezn'iu serdtsa. Kardiologiia. 2014; 9: 7–23. [in Russian]
________________________________________________
1. Kannel WB. Blood pressure as a cardiovascular risk factor. Prevention and treatment. JAMA 1996; 275: 1576.
2. Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 10: 4–12. [in Russian]
3. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–219.
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106 (25): 3143–421.
5. Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.
6. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399–407.
7. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122 (3): 290–300.
8. Leonova M.V., Shteinberg L.L., Belousov Iu.B. i dr. Farmakoepidemiologiia arterial'noi gipertonii v Rossii: analiz priverzhennosti vrachei (po rezul'tatam issledovaniia PIFAGOR IV). Systemic Hypertension. 2015; 1: 19–25. [in Russian]
9. Lee S-A, Choi H-M, Park H-J et al. Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy. Korean J Intern Med 2014; 29: 315–24.
10. Wang JG, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview. Hypertension 2007; 50: 181–8.
11. Mancia G, Grassi. Combination treatment of hypertension. High Blood Pressure1994; 5: 5–7.
12. Elliott W, Meyer P. Incident diabetes in clinical trial of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7.
13. Fleckenstein A, Tritthard H, Fleckenstein B et al. Pflugers Arch Physiol 1969; 307: 25.
14. Angeli F, Verdecchia P, Reboldi GP et al. Calcium channel blockade to prevent stroke in hypertension: meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens 2004; 17 (9): 817–22.
15. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503–10.
16. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–26.
17. Preobrazhenskii D.V., Vyshinskaia I.D., Nekrasova N.I. Bisoprolol – vysokoselektivnyi beta-adrenoblokator: klinicheskaia farmakologiia i opyt pri lechenii serdechno-sosudistykh zabolevanii. Consilium Medicum. 2010; 10 (11): 138–43. [in Russian]
18. Jabbour A, Macdonald PS, Keogh AM et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized cross-over trial. J Am Coll Cardiol 2010; 55 (17): 1780–7.
19. Kjekshus JK. Comments on beta-blockers: heart rate reduction, a mechanism of action. Eur Heart J 1985; 6: 29.
20. Bоhn M, Cotton D, Foster L et al. Impact of resting heart rate on mortality, disability, cognitive decline in patients after ischaemic stroke. Eur Heart J 2012; 33: 2804–12.
21. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and ounger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121–3.
22. Czarnecka D, Koch EMW, Gottwald-Hostalek U. Benefits of afixed-dose combination of bisoprolol and amlodipine in the treatment of hypertension in daily practice: results of more than 4000 patients. Curr Med Res Opin 2015; 1–7.
23. Hostalek Ulrike, Czarnecka Danuta, Koch Ernst MW. Treatment of Hypertensive Patients with a Fixed-Dose Combination of Bisoprolol and Amlodipine: Results of a Cohort study with More Than 10,000 Patients. The Author (s) 2015. http://creativecommons.org/licenses/ by-nc/4.0/
24. Nedogoda S.V., Salasiuk A.S., Tsoma V.V., Chumachek E.V. Vliianie fiksirovannoi kombinatsii amlodipina i bisoprolola na sosudistuiu elastichnost' u patsientov s arterial'noi gipertenziei. Consilium Medicum. 2015; 17 (10): 8–11. [in Russian]
25. Chesnikova A.I., Safronenko V.A., Kolomatskaia O.E. Otsenka effektivnosti fiksirovannoi kombinatsii bisoprolola i amlodipina v ambulatornom lechenii bol'nykh s arterial'noi gipertoniei i ishemicheskoi bolezn'iu serdtsa. Kardiologiia. 2014; 9: 7–23. [in Russian]
2. Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 10: 4–12. [in Russian]
3. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–219.
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106 (25): 3143–421.
5. Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.
6. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399–407.
7. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122 (3): 290–300.
8. Leonova M.V., Shteinberg L.L., Belousov Iu.B. i dr. Farmakoepidemiologiia arterial'noi gipertonii v Rossii: analiz priverzhennosti vrachei (po rezul'tatam issledovaniia PIFAGOR IV). Systemic Hypertension. 2015; 1: 19–25. [in Russian]
9. Lee S-A, Choi H-M, Park H-J et al. Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy. Korean J Intern Med 2014; 29: 315–24.
10. Wang JG, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview. Hypertension 2007; 50: 181–8.
11. Mancia G, Grassi. Combination treatment of hypertension. High Blood Pressure1994; 5: 5–7.
12. Elliott W, Meyer P. Incident diabetes in clinical trial of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7.
13. Fleckenstein A, Tritthard H, Fleckenstein B et al. Pflugers Arch Physiol 1969; 307: 25.
14. Angeli F, Verdecchia P, Reboldi GP et al. Calcium channel blockade to prevent stroke in hypertension: meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens 2004; 17 (9): 817–22.
15. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503–10.
16. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–26.
17. Preobrazhenskii D.V., Vyshinskaia I.D., Nekrasova N.I. Bisoprolol – vysokoselektivnyi beta-adrenoblokator: klinicheskaia farmakologiia i opyt pri lechenii serdechno-sosudistykh zabolevanii. Consilium Medicum. 2010; 10 (11): 138–43. [in Russian]
18. Jabbour A, Macdonald PS, Keogh AM et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized cross-over trial. J Am Coll Cardiol 2010; 55 (17): 1780–7.
19. Kjekshus JK. Comments on beta-blockers: heart rate reduction, a mechanism of action. Eur Heart J 1985; 6: 29.
20. Bоhn M, Cotton D, Foster L et al. Impact of resting heart rate on mortality, disability, cognitive decline in patients after ischaemic stroke. Eur Heart J 2012; 33: 2804–12.
21. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and ounger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121–3.
22. Czarnecka D, Koch EMW, Gottwald-Hostalek U. Benefits of afixed-dose combination of bisoprolol and amlodipine in the treatment of hypertension in daily practice: results of more than 4000 patients. Curr Med Res Opin 2015; 1–7.
23. Hostalek Ulrike, Czarnecka Danuta, Koch Ernst MW. Treatment of Hypertensive Patients with a Fixed-Dose Combination of Bisoprolol and Amlodipine: Results of a Cohort study with More Than 10,000 Patients. The Author (s) 2015. http://creativecommons.org/licenses/ by-nc/4.0/
24. Nedogoda S.V., Salasiuk A.S., Tsoma V.V., Chumachek E.V. Vliianie fiksirovannoi kombinatsii amlodipina i bisoprolola na sosudistuiu elastichnost' u patsientov s arterial'noi gipertenziei. Consilium Medicum. 2015; 17 (10): 8–11. [in Russian]
25. Chesnikova A.I., Safronenko V.A., Kolomatskaia O.E. Otsenka effektivnosti fiksirovannoi kombinatsii bisoprolola i amlodipina v ambulatornom lechenii bol'nykh s arterial'noi gipertoniei i ishemicheskoi bolezn'iu serdtsa. Kardiologiia. 2014; 9: 7–23. [in Russian]
Авторы
Р.И.Стрюк
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
rstryuk@list.ru
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
rstryuk@list.ru
________________________________________________
R.I.Striuk
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
rstryuk@list.ru
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
rstryuk@list.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.